Suppr超能文献

左旋多巴-卡比多巴肠凝胶单药治疗:GLORIA 注册研究的人口统计学、疗效和安全性。

Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.

机构信息

Department of Neurology, Innsbruck Medical University, Austria.

AbbVie, Inc., North Chicago, IL, USA.

出版信息

J Parkinsons Dis. 2019;9(3):531-541. doi: 10.3233/JPD-191605.

Abstract

BACKGROUND

Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) provides stable plasma levodopa concentrations and reduces motor fluctuations in advanced Parkinson's disease (PD) patients.

OBJECTIVE

To compare the effectiveness and safety of LCIG monotherapy vs polytherapy in patients in the GLORIA registry.

METHODS

This was a post hoc analysis of a 24-month, multinational observational registry where advanced PD patients with persistent motor complications received LCIG (with adjunctive PD treatment, as necessary). Patients were categorized retrospectively into three stable treatment groups: LCIG monotherapy, LCIG in combination with oral levodopa only ("levodopa monotherapy" [including nighttime oral levodopa]), or LCIG in combination with any other antiparkinsonian medication ("LCIG polytherapy").

RESULTS

Of 356 patients, 208 were on stable regimens (LCIG monotherapy n = 80; levodopa monotherapy n = 47; LCIG polytherapy n = 81). Baseline characteristics were similar across groups. LCIG monotherapy showed significant improvements until month 18 in activities of daily living and quality of life, and until month 24 for Unified Parkinson's Disease Rating Scale (UPDRS) motor examination (p < 0.05), "Off" time (p < 0.001), "On" time with dyskinesia (p < 0.01), and non-motor symptoms (p < 0.01). More patients in the levodopa monotherapy and LCIG polytherapy groups experienced treatment-related adverse drug reactions (ADRs) including dyskinesias and serious ADRs than did patients in the LCIG monotherapy group. There were few polyneuropathy-related ADRs, of which one case of polyneuropathy led to discontinuation from the Levodopa monotherapy group.

CONCLUSIONS

These data demonstrate that LCIG monotherapy is an effective treatment option in appropriate advanced PD patients; however, definitive baseline clinical predictors identifying patients who can discontinue concomitant oral therapy have not yet been defined.

摘要

背景

左旋多巴-卡比多巴肠凝胶(LCIG)持续输注可稳定血浆左旋多巴浓度,并减少晚期帕金森病(PD)患者的运动波动。

目的

比较 GLORIA 注册研究中 LCIG 单药治疗与联合治疗的疗效和安全性。

方法

这是一项为期 24 个月的多国观察性注册研究的事后分析,其中接受 LCIG 治疗的晚期 PD 患者持续存在运动并发症(必要时联合 PD 治疗)。患者回顾性分为三组稳定治疗:LCIG 单药治疗、LCIG 联合口服左旋多巴(包括夜间口服左旋多巴)单药治疗或 LCIG 联合任何其他抗帕金森病药物治疗(LCIG 联合治疗)。

结果

356 例患者中,208 例患者稳定(LCIG 单药治疗 n=80;左旋多巴单药治疗 n=47;LCIG 联合治疗 n=81)。各组基线特征相似。LCIG 单药治疗直至第 18 个月时在日常生活活动和生活质量方面,以及直至第 24 个月时在统一帕金森病评定量表(UPDRS)运动检查(p<0.05)、“关期”(p<0.001)、“开期”伴运动障碍(p<0.01)和非运动症状(p<0.01)方面均有显著改善。左旋多巴单药治疗和 LCIG 联合治疗组更多患者出现与治疗相关的药物不良反应(ADR),包括运动障碍和严重 ADR,而 LCIG 单药治疗组患者较少。很少有与多发性神经病相关的 ADR,其中一例多发性神经病导致左旋多巴单药治疗组患者停药。

结论

这些数据表明,LCIG 单药治疗是适合的晚期 PD 患者的有效治疗选择;然而,尚未确定明确的基线临床预测因素来确定可以停用联合口服治疗的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验